TNF and juvenile idiopathic arthritis: A retrospective study of ERA patients who had failed anti-TNF therapy reported significant improvement in JIA disease activity, measured using the Juvenile Arthritis Disease Activity Score (JADAS) after treatment with secukinumab [54].